Xiong Cai

2.8k citations
71 papers · 2.2k indexed · h-index 25
Topics
Rheumatoid Arthritis Research and Therapies (16 papers)Histone Deacetylase Inhibitors Research (7 papers)Phytochemistry and Biological Activities (7 papers)

In The Last Decade

Xiong Cai

68 papers receiving 2.2k citations

Peers

Xiong Cai
Comparison fields: 5 of 113
  • Molecular Biology 1.3k
  • Oncology 398
  • Pharmacology 384
  • Pharmacology 294
  • Organic Chemistry 267
Replace Megumi Funakoshi‐Tago with:
Megumi Funakoshi‐Tago Japan
Tai‐Ping Fan United Kingdom
A.R.M. Ruhul Amin United States
Duncan H. Mak United States
Matthias Wirth Germany
Feng Jin China
Mee‐Hyun Lee South Korea
Hyen Joo Park South Korea
Rong Hu United States
Xiong Cai relative to Megumi Funakoshi‐Tago Japan Megumi Funakoshi‐Tago's profile →
Citations per field
00.5×
Megumi Funakoshi‐Tago · 1×
Citations per year

Countries citing papers authored by Xiong Cai

Since Specialization
Citations

This map shows the geographic impact of Xiong Cai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiong Cai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiong Cai more than expected).

Fields of papers citing papers by Xiong Cai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiong Cai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiong Cai. The network helps show where Xiong Cai may publish in the future.

Co-authorship network of co-authors of Xiong Cai

This figure shows the co-authorship network connecting the top 25 collaborators of Xiong Cai. A scholar is included among the top collaborators of Xiong Cai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiong Cai. Xiong Cai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 4
2 7
3 38
4 6
5 8
6 18
7 65
8 12
9 23
10 40
11 22
12 33
13 16
14 68
15 188
16 182
17 67
18 44
19 8
20
Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis.
34

About Xiong Cai

Xiong Cai is a scholar working on Pharmacology, Rheumatology and Biochemistry, having authored 71 papers that have together received 2.2k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (16 papers), Histone Deacetylase Inhibitors Research (7 papers) and Phytochemistry and Biological Activities (7 papers). The work is most often cited by research in Pharmacology (384 citations), Complementary and alternative medicine (235 citations) and Molecular Biology (1.3k citations). Xiong Cai has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Hua Zhou, Cheng-Jung Lai, Changgeng Qian, Hui Qu, Rudi Bao, Hai-Xiao Zhai, Ling Yin, Liang Liu, Yuen Fan Wong and Hong‐Xi Xu. Their work appears in journals such as Nucleic Acids Research, ACS Nano and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026